Sutro Biopharma Announces Participation in Upcoming Investor Conferences
Sutro Biopharma, Inc. announced that its management team will participate in several investor conferences scheduled for November and December 2026.
Stocks · News reference
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced that management will participate in multiple investor conferences from November through December 2026, including events hosted by Stifel, Truist Securities, UBS, Jefferies, and Piper Sandler. Live webcasts and archived replays will be available on the company's investor relations website.
StrongPoint Reports Third Quarter 2026 Financial Results
StrongPoint ASA reported a 14% year-over-year revenue increase to NOK 364 million for the third quarter of 2026, alongside a net loss of NOK 2.35 million.
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006
Sutro Biopharma has initiated a Phase 1 clinical trial for STRO-006, an antibody-drug conjugate targeting integrin β6 for the treatment of solid tumors.
Sutro Biopharma Doses First Patient In Its Phase 1 Trial Of STRO-006 In Patients With Range Of Solid Tumors; Initial Clinical Data Expected In H2 2027
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target